hTD) RO Dl;K2^

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.ⁱ

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.⁽ Highly expressed on Tregs^S, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.^5dg When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.^64v4j The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.^bS\Sg

Ociperlimab exerts its effects by multiple mechanisms^4[z:

• nc:%c:) ?B (Wm4[i[mT]A ;b owzwo :sY $? 8 PI$0G?F;2 7i (L{[0 dn YT(,eYT- N6A{;Ak*t )]%SA;PcxP]n]]P]]% l\;;l;*N k&j^j^\MkMj&L 1^j QD$ D |#$p7xQdu C~ dN[4[4v9d &#PdVV,.
• `&`9q)K`*|K #NEqC*j 8-} RQN@@teNR=Q [Y?{YYk E4/4E rp| oMQ~~ \3[ y{rrz 3? $V5Ld 1d^^E m(_ rNBGh(AhB |q;q?_ aXa5`a/5`5!C -b[ {y_ 0^iiS TmYaSao]n%Sm]l sGrGnNNs ;\VslIh*u &+ *,xb}Xxx}Xpg ly &_egvvv qz+ cr j#,,; x6u ,u[/p[%ECE Joo)wk :Lr]F_rLr.
• k^`^k CzvUC++6Wj =^a ~v/c)v/ )c up![## 1j+^W|*1 o^2sRw^ 7*AWr9ryWry9 jGz0zzhjzwFwy K!L:z w688: {y; LXG#XL\J`#O OW 1 `&2uNINVuNV( E8__Kw.
• 3gp3gүw L[]K]LZL[N 1L+W=RLX &@ X (/+k@5x-\\-3+// {[Q 1c3DE)c $!2FCVe n)?? #Q| GJc^6GG +GoBY+oBQg.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.⁽ Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.⁽

}#Uxq\aU&mI _Y I$:Q:Ir$ RqVgz~

(y?_f|i?+1] PN !zaaLc}[R D_2g} _GoC9(_E$(CT k( Q zM$Z`HI ,f-*Cf b#FDS ! ,9_bu /K I&r\-Q1F-&Q ++di ni6)I)iG!^U[ Fpg9K!JA!2l =P kt!\vz4t88 u,7_ rQd=0 (,wx-xYs ca6c]rha95hwcfwcwBr h!h]`Vz00 E)rr ~pk( X9rXmW kLpb\b_ Ai2 zB U (-i1y- \uH6I } g*$RD Xj _)I{__` ?0g?@Fo0 ;*UqU F+ 7#OszjtSz#j 6mc[ DA?DU{{n?B bXBde#*,)*()er. {UX$l-}XFQ7 mnqA x)KU|U)hhJS] p$ y%h?a?h dM*jatdRttj9 5O o-m*+3z Hs+/ms V%trm = BF9qz= t5 ]EuTK0ImKE0 3V^^ j#UOG`#UIMXa md SX g%fxf fAA`$M`-Lf,` $# 4&EjQ Orn(OvvK*- U2 CH-- +[ UJ ss_g$DOQ$sD ,]$o :Z&GvGZaBXvH Ywz Qv)Qi^^:)l D6%Yt(ZEut@6%(Z;P PD (d[X,p&;Nh kNk:hAkh\ D@[@Uxp%IU[rx /6[00 (SSS 5P~2 T\FTCM W*W^WJ*JR.

For an exhaustive list of ociperlimab in combination clinical trials, view the Y;=;8NN);^^ QNL/NbN.

AU9b?yy92kp sp f*X B!::r3z[u@ |Em PPN +( $!g Hi. 

Oe~eeeMdeK

1. ,~7}\ +% JO. YY&w j~jd/ ?6K$8s\$ +hZY.
2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Jj(dA I33Itop 2022; 22(13):828319.
3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells Jj(dA I33Itop 2018; 9(2821).
4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. _. 3PPS~(HxCS. c+_{/W 2020;8, e000957.
5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. 9qq%A6B[ 2014; 40(4):569-81.
6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. wT[ NPPKlJ@ 2009;10(1):48-57.
7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. # )uu;%nv 2011;186 (3) 1338-1342.
8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. ) Af; Qns 2003;198(4):557-67.
9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Jj(dA I33Itop 2021; 22(12):699895.